All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Article

June 15, 2007

Champix recommended by UK body

The National Institute for Health and Clinical Excellence (NICE) in the UK has recommended Pfizer?s Champix (varenicline) for use on the NHS for adult smokers who have expressed a desire to quit.

The National Institute for Health and Clinical Excellence (NICE) in the UK has recommended Pfizer's Champix (varenicline) for use on the NHS for adult smokers who have expressed a desire to quit. This gives UK smokers access to another important treatment option to help them quit their addiction.

NICE concluded that varenicline was "superior to NRT [nicotine replacement therapy] and bupropion in achieving continuous abstinence." In light of this, the agency declared that its use in smoking cessation was "likely to be a cost-effective use of NHS resources".

"This guidance means that smokers who are serious about stopping have another choice from a good range of clinically proven treatments," said Robert West, professor of Health Psychology at University College London. "Smokers who combine treatments with the right support — for instance from smoking cessation services — could significantly increase their odds of successfully quitting for life."

Chantix (varenicline) received FDA approval as an aid to smoking cessation in May last year. In the EU, Champix received marketing authorization in September 2006 for the same purpose. The drug was developed by Pfizer as such an aid through its novel mechanism of action targeting the specific receptor to which nicotine binds. It is believed to work by reducing the severity of the smoker's urge to smoke. It blocks the pleasure receptors in the brain associated with cigarette smoking and nicotine, and reduces the level of withdrawal symptoms that often cause a return to the addiction.

Smoking, the leading cause of preventable death worldwide, is responsible for five million deaths each year. By 2010,WHO estimates the annual global cost of tobacco-related illness to be approximately $500 billion.

www.pfizer.com

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
Related Content
Advertisement
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 29th 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 29th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 29th 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 29th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Specification Equivalence: A Practical Approach to Method and Acceptance Criteria Equivalence
August 29th 2025

Specification Equivalence: A Practical Approach to Method and Acceptance Criteria Equivalence

Gail Reed Joseph A. Albanese Yelena Ionova J. Mark Wiggins
Feb 19, 2020 Foster City / CA / USA - Gilead sign at their headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs | Image Credit: © Sundry Photography - stock.adobe.com
August 29th 2025

Gilead Sciences’ HIV PrEP Injectable Approved by European Commission

Patrick Lavery
Related Content
Advertisement
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 29th 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 29th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 29th 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 29th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Specification Equivalence: A Practical Approach to Method and Acceptance Criteria Equivalence
August 29th 2025

Specification Equivalence: A Practical Approach to Method and Acceptance Criteria Equivalence

Gail Reed Joseph A. Albanese Yelena Ionova J. Mark Wiggins
Feb 19, 2020 Foster City / CA / USA - Gilead sign at their headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs | Image Credit: © Sundry Photography - stock.adobe.com
August 29th 2025

Gilead Sciences’ HIV PrEP Injectable Approved by European Commission

Patrick Lavery
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.